P&G Health Q3 results: Net profit surges over 26% to ₹91 crore, board declares interim dividend

While the company’s revenue from operations remained flat on a year-on-year basis at ₹309.77 crore in the third quarter of the 2024-25 fiscal year, it fell 1.61% sequentially from ₹313.41 crore in Q2 FY25.

P&G Health’s total income stood at ₹313.73 crore in Q3 FY25, dipping 0.45% YoY from ₹315.15 crore in the third quarter of the 2023-24 fiscal year (Q3 FY24)

The company’s total expenses fell 10.86% YoY to ₹192.04 crore in the quarter under review, compared to ₹215.43 crore in the year-ago period.

“This quarter was a period of strategic reinforcement as we took proactive steps to strengthen our supply network. We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organisation structure. We are confident that this strategy will enable us to meet the evolving needs of our consumers and healthcare professionals alike,” Milind Thatte, the Managing Director of P&G Health India commented.

Board approves interim dividend

P&G Health India’s board of directors green-lit an interim dividend of ₹80 per equity share with a face value of ₹10 each for the Financial Year 2024-25.

The company fixed Friday, February 21, 2025, as the record date for determining the eligibility for the dividend. It will make the payment on or before March 7.

Stock performance

Shares of P&G Health India closed in the green at ₹5,395.50 apiece, down 2.54% on the National Stock Exchange (NSE) after the company announced its Q3 earnings.

The stock gained 0.21% over the past five days and 3.77% in the last month. It rose 3.83% in the past six months and 3.37% on a year-to-date basis.

P&G Health India has a total market capitalisation of ₹8,956.20 crore as of February 12, 2025, on the NSE.